This is the authors' abstract. We don't add key points for this paper.
To report longer-term outcomes for five adolescents with symptomatic SMA Type II/III treated with nusinersen who participated in SHINE (NCT02594124).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Day et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: